✦ LIBER ✦

Multiple Myeloma: A Multifactorial Problem for the Hand Surgeon as a Patient

✍ Scribed by Al-Qattan, M. M.

Book ID: 116657441
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 70 KB
Volume: 32
Category: Article
ISSN: 0363-5023
DOI: 10.1016/j.jhsb.2006.09.016

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The Surgeon as a Hand Patient: The Clini

The Surgeon as a Hand Patient: The Clinical and Psychological Impact of Hand and Wrist Fractures

✍ Kingsley R. Chin; Jess H. Lonner; Beryl S. Jupiter; Jesse B. Jupiter 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 21 KB

The SCID mouse as a model for multiple m

The SCID mouse as a model for multiple myeloma

✍ Els J. M. Ahsmann; Maarten J. D. van Tol; Joy Oudeman-Gruber; Henk Lokhorst; Fon 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 826 KB

A067 Thalidomide/Dexamethasone (THALDEX)

A067 Thalidomide/Dexamethasone (THALDEX) as Salvage Therapy for Multiple Myeloma Patients First Relapsing

✍ Charlinski, G; Jedrzejczak, WW; Wiater, EM; Dwilewicz-Trojaczek, J 📂 Article 📅 2009 🏛 CIG Media Group, LP. 🌐 English ⚖ 91 KB

The patient as text: a challenge for pro

The patient as text: a challenge for problem-based learning

✍ Nuala P Kenny; Brenda L Beagan 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 91 KB

BAFF and APRIL as osteoclast-derived sur

BAFF and APRIL as osteoclast-derived survival factors for myeloma cells: a rationale for TACI-Fc treatment in patients with multiple myeloma

✍ Abe, M; Kido, S; Hiasa, M; Nakano, A; Oda, A; Amou, H; Matsumoto, T 📂 Article 📅 2006 🏛 Nature Publishing Group 🌐 English ⚖ 124 KB

Bortezomib, thalidomide, and dexamethaso

Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma : A retrospective study

✍ Jonathan L. Kaufman; Ajay Nooka; Mark Vrana; Charise Gleason; L. Thompson Heffne 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 172 KB

## Abstract ## BACKGROUND: This single‐center retrospective study determined the efficacy of bortezomib, thalidomide, and dexamethasone (BTD) as induction for patients with multiple myeloma (MM) who were eligible for autologous stem cell transplantation (ASCT). ## METHODS: Patients with symptoma